Tumor Mutational Burden: Result Reporting and Application to Improve Patient Care
Ahmet Zehir, PhD
Jonathan Nowak, M.D.,Ph.D.
This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA.
As tumor mutational burden (TMB) is gaining traction as a predictive biomarker for immunotherapy, the challenge of reporting TMB back to the treating oncologists and patients in an informative way still exists. In this webinar, we will discuss strategies of implementing TMB in the clinical laboratory, how different TMB values reported from various assays compare to each other, and how to communicate the results in a clear way.
- Describe challenges and opportunities in the implementation of TMB testing in the clinical laboratory.
- Discuss the various ways by which TMB can be reported back to the clinicians and patients
Recording Date: September 26, 2018
Duration: 1 hr
Level of Instruction: Basic
CE Credit for this course has expired.
This webinar is part 3 of a three-part series exploring how measuring tumor mutational burden can improve patient care.
For more information on this series, please go here.
This program has been supported through an educational grant from Bristol-Myers Squibb.
Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.